Patents by Inventor Vincenzo Garzya

Vincenzo Garzya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENTS FOR OBSESSIVE COMPULSIVE DISORDER
    Publication number: 20240050427
    Abstract: The present invention provides for an effective pharmacological therapy for obsessive compulsive disorder.
    Type: Application
    Filed: August 3, 2023
    Publication date: February 15, 2024
    Inventors: Vincenzo GARZYA, Jon TANCOCK, Nicolas Thierry SIREAU, Trevor ROBBINS
  • Compounds which have activity at M1 receptor and their uses in medicine
    Patent number: 8481566
    Abstract: Compounds of formula (I) and salts and solvates are provided: wherein R4 is fluoro, R5 is selected from hydrogen, halogen, cyano, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C1-6alkoxy, and C1-6alkoxy substituted with one or more fluorine atoms; and R6 is selected from halogen, cyano, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C3-6cycloalkyl, C3-6cycloalkyl substituted with one or more fluorine atoms, C1-6alkoxy and C1-6alkoxy substituted with one or more fluorine atoms, and Q is hydrogen or C1-6alkyl. The compounds are expected to be useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.
    Type: Grant
    Filed: September 10, 2007
    Date of Patent: July 9, 2013
    Assignee: Glaxo Group Limited
    Inventors: Brian Budzik, David Gwyn Cooper, Ian Thomson Forbes, Vincenzo Garzya, Jian Jin, Dongchuan Shi, Graham Walker
  • Compounds which have activity at Mreceptor and their uses in medicine
    Patent number: 8426443
    Abstract: Compounds of formula (I) or a salt thereof are provided: wherein R4, R5, R6, Q, A, Y and R are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic disorders, cognitive impairments and Alzheimer's Disease are disclosed. The invention further discloses pharmaceutical compositions comprising the compounds.
    Type: Grant
    Filed: August 23, 2012
    Date of Patent: April 23, 2013
    Assignee: Glaxo Group Limited
    Inventors: David Gwyn Cooper, Ian Thomson Forbes, Vincenzo Garzya, Dale James Johnson, Graeme Irvine Stevenson, Paul Adrian Wyman
  • Compounds which have activity at Mreceptor and their uses in medicine
    Patent number: 8344000
    Abstract: Compounds of formula (I) and salts thereof are provided: wherein R4, R5, R6, Q, A, and Y are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic disorders, cognitive impairments and Alzheimer's Disease are disclosed. The invention further discloses pharmaceutical compositions comprising the compounds.
    Type: Grant
    Filed: September 18, 2008
    Date of Patent: January 1, 2013
    Assignee: Glaxo Group Limited
    Inventors: David Gwyn Cooper, Ian Thomson Forbes, Vincenzo Garzya, Dale James Johnson, Paul Adrian Wyman
  • Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine
    Publication number: 20120316196
    Abstract: Compounds of formula (I) or a salt thereof are provided: wherein R4, R5, R6, Q, A, Y and R are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic disorders, cognitive impairments and Alzheimer's Disease are disclosed. The invention further discloses pharmaceutical compositions comprising the compounds.
    Type: Application
    Filed: August 23, 2012
    Publication date: December 13, 2012
    Inventors: David Gwyn Cooper, Ian Thomson Forbes, Vincenzo Garzya, Dale James Johnson, Graeme Irvine Stevenson, Paul Adrian Wyman
  • Compounds which have activity at M1 receptor and their uses in medicine
    Publication number: 20120316202
    Abstract: Compounds of the general formula And their use in the treatment of psychotic disorders and cognitive impairment are disclosed.
    Type: Application
    Filed: August 14, 2012
    Publication date: December 13, 2012
    Inventors: David Gwyn COOPER, Ian Thomson Forbes, Vincenzo Garzya, Jian Jin, Yann Louchart, Graham Walker, Paul Adrian Wyman
  • Compounds which have activity at Mreceptor and their uses in medicine
    Patent number: 8299257
    Abstract: Compounds of formula (I) or a salt thereof are provided: wherein R4, R5, R6, Q, A, Y and R are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic disorders, cognitive impairments and Alzheimer's Disease are disclosed. The invention further discloses pharmaceutical compositions comprising the compounds.
    Type: Grant
    Filed: September 18, 2008
    Date of Patent: October 30, 2012
    Assignee: Glaxo Group Limited
    Inventors: David Gwyn Cooper, Ian Thomson Forbes, Vincenzo Garzya, Dale James Johnson, Graeme Irvine Stevenson, Paul Adrian Wyman
  • Compounds which have activity at Mreceptor and their uses in medicine
    Patent number: 8288412
    Abstract: Compounds of formula (I) and salts are provided: wherein R5 is selected from halogen, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C1-6 alkoxy, C1-6 alkoxy substituted with one or more fluorine atoms, and cyano; R6 is selected from halogen, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C3-6cycloalkyl, C3-6cycloalkyl substituted with one or more fluorine atoms, C1-6 alkoxy, C1-6 alkoxy substituted with one or more fluorine atoms, and cyano; and Q is hydrogen or C1-6alkyl. The compounds are M1 agonists and are useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.
    Type: Grant
    Filed: September 27, 2006
    Date of Patent: October 16, 2012
    Assignee: Glaxo Group Limited
    Inventors: Brian Budzik, David Gwyn Cooper, Ian Thomson Forbes, Vincenzo Garzya, Jian Jin, Dongchuan Shi, Paul William Smith, Graham Walker
  • Compounds which have activity at Mreceptor and their uses in medicine
    Patent number: 8283364
    Abstract: Compounds of formula (I) and salts are provided: wherein R4 is fluoro, R5 is selected from hydrogen, halogen, cyano, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C1-6alkoxy, and C1-6alkoxy substituted with one or more fluorine atoms; and R6 is selected from halogen, cyano, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C3-6cycloalkyl, C3-6cycloalkyl substituted with one or more fluorine atoms, C1-6alkoxy and C1-6alkoxy substituted with one or more fluorine atoms, and Q is hydrogen or C1-6alkyl. The compounds are expected to be useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.
    Type: Grant
    Filed: September 27, 2006
    Date of Patent: October 9, 2012
    Assignee: Glaxo Group Limited
    Inventors: Brian Budzik, David Gwyn Cooper, Ian Thomson Forbes, Vincenzo Garzya, Jian Jin, Dongchuan Shi, Paul William Smith, Graham Walker
  • Compounds which have activity at Mreceptor and their uses in medicine
    Patent number: 8278328
    Abstract: Compounds of formula (I) or a salt thereof are provided: wherein R4, R5, R6, Q, A, Y and R are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic disorders, cognitive impairments and Alzheimer's Disease are disclosed. The invention further discloses pharmaceutical compositions comprising the compounds.
    Type: Grant
    Filed: September 18, 2008
    Date of Patent: October 2, 2012
    Assignee: Glaxo Group Limited
    Inventors: David Gwyn Cooper, Ian Thomson Forbes, Vincenzo Garzya, Dale James Johnson, Graeme Irvine Stevenson, Paul Adrian Wyman
  • BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE
    Publication number: 20120041027
    Abstract: Compounds of formula (I) and salts and solvates are provided: wherein Uses of the compounds for therapy, for example in the treatment of psychotic disorders and cognitive impairment, are also disclosed.
    Type: Application
    Filed: October 27, 2011
    Publication date: February 16, 2012
    Inventors: David Gwyn COOPER, Ian Thomson Forbes, Vincenzo Garzya, Jian Jin, Yann Louchart, Graham Walker, Paul Adrian Wyman
  • BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE
    Publication number: 20120041028
    Abstract: Compounds of formula (I), salts and solvates are provided: Uses of the compounds for therapy, for example in the treatment of psychotic disorders and cognitive impairment, are also disclosed.
    Type: Application
    Filed: October 27, 2011
    Publication date: February 16, 2012
    Inventors: David Gwyn COOPER, Ian Thomas Forbes, Vincenzo Garzya, Jian Jin, Yann Louchart, Graham Walker, Paul Adrian Wyman
  • BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE
    Publication number: 20110207777
    Abstract: Compounds of formula (I), salts and solvates are provided, Uses of the compounds for therapy, for example in the treatment of psychotic disorders and cognitive impairment, are also disclosed.
    Type: Application
    Filed: March 20, 2007
    Publication date: August 25, 2011
    Inventors: David Gwyn Cooper, Ian Thomson Forbes, Vincenzo Garzya, Jian Jin, Yann Louchart, Graham Walker, Paul Adrian Wyman
  • Compounds Which Have Activity At M1 Receptor And Their Uses In Medicine
    Publication number: 20110130423
    Abstract: Compounds of formula (I) and salts thereof are provided: wherein R4, R5, R6, Q, A, and Y are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic disorders, cognitive impairments and Alzheimer's Disease are disclosed. The invention further discloses pharmaceutical compositions comprising the compounds.
    Type: Application
    Filed: September 18, 2008
    Publication date: June 2, 2011
    Inventors: David Gwyn Cooper, Ian Thomas Forbes, Vincenzo Garzya, Dale James Johnson, Paul Adrian Wyman
  • TRIAZOLE AMIDE DERIVATIVES FOR USE IN THERAPY
    Publication number: 20110065725
    Abstract: The invention relates to triazole amide derivatives of formula (I) for use in therapy, in particular for treating diseases and conditions mediated by antagonism of the mGluR5 receptor, in particular substance related disorders. The invention also relates to certain novel derivatives. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.
    Type: Application
    Filed: March 16, 2009
    Publication date: March 17, 2011
    Applicant: GLAXO GROUP LIMITED
    Inventors: Vincenzo Garzya, Stephen Paul Watson
  • BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE
    Publication number: 20100280071
    Abstract: Compounds of formula (I), salts and solvates are provided: Uses of the compounds for therapy, for example in the treatment of psychotic disorders and cognitive impairment, are also disclosed.
    Type: Application
    Filed: March 20, 2007
    Publication date: November 4, 2010
    Inventors: David Gwyn Cooper, Ian Thomson Forbes, Vincenzo Garzya, Jian Jin, Yann Louchart, Graham Walker, Paul Adrian Wyman
  • Compounds which have activity at M1 receptor and their uses in medicine
    Publication number: 20100210687
    Abstract: Compounds of formula (I) or a salt thereof are provided: wherein R4, R5, R6, Q, A, Y and R are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic disorders, cognitive impairments and Alzheimer's Disease are disclosed. The invention further discloses pharmaceutical compositions comprising the compounds.
    Type: Application
    Filed: September 18, 2008
    Publication date: August 19, 2010
    Inventors: David Gwyn Cooper, Ian Thomason Forbes, Vincenzo Garzya, Dale James Johnson, Graeme Irvine Stevenson, Paul Adrian Wyman
  • Compounds which have activity at M1 receptor and their uses in medicine
    Publication number: 20100204272
    Abstract: Compounds of formula (I) or a salt thereof are provided: wherein R4, R5, R6, Q, A, Y and R are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic disorders, cognitive impairments and Alzheimer's Disease are disclosed. The invention further discloses pharmaceutical compositions comprising the compounds.
    Type: Application
    Filed: September 18, 2008
    Publication date: August 12, 2010
    Inventors: David Gwyn Cooper, Ian Thomson Forbes, Vincenzo Garzya, Dale James Johnson, Graeme Irvine Stevenson, Paul Adrian Wyman
  • BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE
    Publication number: 20100190825
    Abstract: Compounds of formula (I) and salts and solvates are provided: wherein Uses of the compounds for the treatment of psychotic disorders and cognitive mpairment, are also disclosed.
    Type: Application
    Filed: March 20, 2007
    Publication date: July 29, 2010
    Inventors: David Gwyn Cooper, Ian Thomson Forbes, Vincenzo Garzya, Jian Jin, Yann Louchart, Graham Walker, Paul Adrian Wyman
  • 2,3,4,5-tetrahydro-1H-3-benzazepines and their medical use
    Patent number: 7504392
    Abstract: The invention provides compounds of the formula or a pharmaceutically acceptable salts thereof. The compounds are useful in therapy, in particular as antipsychotic agents.
    Type: Grant
    Filed: May 28, 2003
    Date of Patent: March 17, 2009
    Assignee: Glaxo Group Limited
    Inventors: Ian Thomson Forbes, Vincenzo Garzya, Andrew Derrick Gribble, Andrew Lightfoot, Andrew H. Payne, Graham Walker